Telaprevir in treatment of chronic hepatitis C: safety issues

Telaprevir in treatment of chronic hepatitis C: safety issues

The aim of review. To analyze results of controlled clinical studies of efficacy and safety of telaprevir within triple antiviral therapy of chronic hepatitis C (CHC) with evaluation of frequency and spectrum of adverse effects (AE), and also approaches of their management.Original positions. Invest...

Full description

Saved in:

Bibliographic Details
Main Author:	T. M. Ignatova
Format:	Article
Language:	Russian
Published:	Gastro LLC 2012-07-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	telaprevir antiviral therapy hepatitis c safety adverse effects dermal reactions anemia
Online Access:	https://www.gastro-j.ru/jour/article/view/1310
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Modern modes of chronic hepatitis C treatment
by: V. T. Ivashkin, et al.
Published: (2012-02-01)

Two ways to one goal: new strategy of antiviral therapy for chronic hepatitis C
by: S. N. Batskikh
Published: (2012-11-01)

Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study
by: D. T. Abrurakhmanov, et al.
Published: (2014-07-01)

Chronic hepatitis C course at elderly and therapeutic approach
by: M. V. Mayevskaya, et al.
Published: (2011-02-01)

Antiviral therapy for chronic hepatitis C: is there a time to change existing standards?
by: D. T. Abdurakhmanov
Published: (2009-02-01)

Application of dicarbamin in treatment of patients by a chronic hepatitis C
by: D. Yu. Konstantinov, et al.
Published: (2011-09-01)

Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis C
by: N. B. Kovaleva
Published: (2014-08-01)

The prognostic value of ferritinemia level in patients with chronic hepatitis C
by: N. C. Sargsyants, et al.
Published: (2013-07-01)

Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study
by: T. Berg, et al.
Published: (2019-01-01)

B-cell non-Hodgkin's lymphoma in the patient with chronic hepatitis C and mixed cryoglobulinemia
by: V. S. Adonyeva, et al.
Published: (2015-03-01)

Sarcoid-like reaction at the patient with chronic hepatitis C on a background of antiviral therapy
by: A. V. Lapshin, et al.
Published: (2010-06-01)

NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy
by: M. V. Mayevskaya, et al.
Published: (2015-12-01)

Interferon-free therapy of chronic hepatitis C: replacement of medications or new treatment paradigm?
by: S. N. Batskikh
Published: (2014-10-01)

Efficacy and safety of new protease inhibitor faldaprevir in treatment of hepatitis C
by: M. V. Mayevskaya, et al.
Published: (2013-12-01)

Modern modes of chronic hepatitis B treatment in daily clinical practice
by: M. V. Mayevskaya, et al.
Published: (2014-11-01)

Telaprevir: options of application in separate patient groups
by: M. V. Mayevskaya, et al.
Published: (2013-10-01)

Investigating the Safety of Fampridine in Patients with Different Stages of Multiple Sclerosis
by: Saeed Vaheb, et al.
Published: (2025-01-01)

Hyperferritinemia at the patient with chronic hepatitis C
by: Ye. N. German, et al.
Published: (2009-02-01)

Chronic hepatitis B and risk of kidney involvement
by: M. V. Mayevskaya, et al.
Published: (2013-05-01)

Hyperhomocisteinemia, hypercysteinemia, glutamate excitotoxicity, taurine deficiency at hepatitis C
by: V. K. Pozdeev, et al.
Published: (2015-07-01)

Impact of hepatic steatosis on the efficacy of antiviral treatment for chronic hepatitis B and the establishment of predictive model: a cohort study
by: Guanghui Ren, et al.
Published: (2025-02-01)

FREQUENCY OF IRON DEFICIENCY ANEMIA IN PREGNANCY, AND ITSASSOCIATED MATERNAL AND PERINATAL OUTCOMES
by: Naila Qamar, et al.
Published: (2024-07-01)

Genetic polymorphism of hepatitis C virus and risk of hepatocellular carcinoma
by: S. N. Mammayev, et al.
Published: (2014-09-01)

Risk of progression and the cause of mortality at chronic viral mixed-hepatitis
by: K. I. Yesmembetov, et al.
Published: (2013-07-01)

Polymorphism of renin — angiotensin system genes in progression of liver fibrosis in patients with chronic hepatitis C
by: O. V. Taratina, et al.
Published: (2014-08-01)

Pegilated interferon α2а in treatment of chronic hepatitis C
by: P. O. Bogomolov, et al.
Published: (2012-09-01)

The impact of genetic polymorphisms of IL28B gene on the efficacy of antiviral therapy of the chronic hepatitis C by using the standard Interferon-<i>α</i>
by: A. V. Lapshin, et al.
Published: (2013-03-01)

Diastolic dysfunction of myocardium and change of <i>Q–T</i> interval at chronic hepatitis C
by: A. A. Konysheva, et al.
Published: (2012-11-01)

Lack of Tissue Virological Response as a Predictor of Relapse in Chronic Hepatitis D after Completion Bulevirtide Therapy
by: P. O. Bogomolov, et al.
Published: (2024-12-01)

Long-term results of antiviral therapy in patients with chronic hepatitis C with sustained virologic response
by: T. M. Ignatova, et al.
Published: (2013-09-01)

Treatment of chronic hepatitis C by cepeginterferon alpha-2b in combination to ribavirin
by: M. V. Mayevskaya, et al.
Published: (2014-08-01)

Seroprevalence of hepatitis B and C virus among a group of hemophilia patients in Kurdistan Region, Iraq
by: Salih A. Hama
Published: (2025-02-01)

Role of alpha-fetoprotein in complex diagnostics of progressing course of chronic hepatitis B and C
by: I. A. Belavina, et al.
Published: (2012-06-01)

Efficacy of pegylated interferon alfa-2b «Algeron» in the treatment of chronic hepatitis C
by: M. V. Mayevskaya, et al.
Published: (2013-03-01)

Oxidative stress in viral hepatitis
by: Huseyin Erdal, et al.
Published: (2024-04-01)

Clinical Practice Guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientific Society of Infectious Disease Specialists for the Diagnosis and Treatment of Chronic Hepatitis C
by: V. T. Ivashkin, et al.
Published: (2023-06-01)

Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study
by: V. T. Ivashkin, et al.
Published: (2014-07-01)

Long-Term Results of the Etiotropic Therapy of Subcompensed Liver Cirrhosis in the Outcome of Chronic Hepatitis C
by: P. O. Bogomolov, et al.
Published: (2020-01-01)

Epidemiological Study of Hepatitis B, C and HIV Cases among the Foreigners Visiting Sulaimani City from 2013 Through 2016
by: Mohammed Omer Mohammed, et al.
Published: (2019-10-01)

Long-Term Monitoring of Liver Fibrosis and Steatosis in Patients with Chronic Hepatitis C after Achieving a Sustained Virologic Response to Antiviral Therapy
by: K. R. Dudina, et al.
Published: (2023-02-01)